Abstract:Abstract Background Clear cell renal cell carcinoma (ccRCC) is one of the most lethal urological malignancies, but the pathogenesis and prognosis of ccRCC remain obscure, which need to be better understand. Methods Differentially expressed genes were identified and function enrichment analyses were performed using three publicly available ccRCC gene expression profiles downloaded from the Gene Expression Omnibus database. The protein-protein interaction and the competing endogenous RNA (ceRNA) networks were visualized by Cytoscape. Multivariate Cox analysis was used to predict an optimal risk mode, and the survival analysis was performed with the Kaplan-Meier curve and log-rank test. Protein expression data were downloaded from Clinical Proteomic Tumor Analysis Consortium database and Human Protein Atlas database, and the clinical information as well as the corresponding lncRNA and miRNA expression data were obtained via The Cancer Genome Atlas database. The co-expressed genes and potential function of candidate genes were explored using data exacted from the Cancer Cell Line Encyclopedia database. Results Of the 1044 differentially expressed genes shared across the three datasets, 461 were upregulated, and 583 were downregulated, which significantly enriched in multiple immunoregulatory-related biological process and tumor-associated pathways, such as HIF-1, PI3K-AKT, P53 and Rap1 signaling pathways. In the most significant module, 36 hub genes were identified and were predominantly enriched in inflammatory response and immune and biotic stimulus pathways. Survival analysis and validation of the hub genes at the mRNA and protein expression levels suggested that these genes, particularly complement component 3 (C3) and fibronectin 1 (FN1), were primarily responsible for ccRCC tumorigenesis and progression. Increased expression of C3 or FN1 was also associated with advanced clinical stage, high pathological grade, and poor survival in patients with ccRCC. Univariate and multivariate Cox regression analysis qualified the expression levels of the two genes as candidate biomarkers for predicting poor survival. FN1 was potentially regulated by miR-429, miR-216b and miR-217, and constructed a bridge to C3 and C3AR1 in the ceRNA network, indicating a critical position of FN1. Conclusions The biomarkers C3 and FN1 could provide theoretical support for the development of a novel prognostic tool to advance ccRCC diagnosis and targeted therapy.

SNORD63 and SNORD96A As the Non-Invasive Diagnostic Biomarkers for Clear Cell Renal Cell Carcinoma

A Novel DNA Methylation Signature Revealed GDF6 and RCC1 As Potential Prognostic Biomarkers Correlated with Cell Proliferation in Clear Cell Renal Cell Carcinoma

Plasma SNORD42B and SNORD111 As Potential Biomarkers for Early Diagnosis of Non-Small Cell Lung Cancer

Expression Signature of Six‐snorna Serves As Novel Non‐invasive Biomarker for Diagnosis and Prognosis Prediction of Renal Clear Cell Carcinoma

A three-snoRNA signature: SNORD15A, SNORD35B and SNORD60 as novel biomarker for renal cell carcinoma

Plasma SNORD83A as a potential biomarker for early diagnosis of non-small-cell lung cancer

Discovery and validation of the prognostic value of the lncRNAs encoding snoRNAs in patients with clear cell renal cell carcinoma

Mir-144-3p As a Novel Plasma Diagnostic Biomarker for Clear Cell Renal Cell Carcinoma.

SNORD15B and SNORA5C: Novel Diagnostic and Prognostic Biomarkers for Colorectal Cancer

Identification of Small Nucleolar RNA SNORD60 As a Potential Biomarker and Its Clinical Significance in Lung Adenocarcinoma.

Serum Exosomal Mir-210 As a Noninvasive Molecular Diagnosis Biomarker in Clear Cell Renal Cell Carcinoma

Identification of a cancer driver gene-associated lncRNA signature for prognostic prediction and immune response evaluation in clear cell renal cell carcinoma

Identification of C3 and FN1 as potential biomarkers associated with progression and prognosis for clear cell renal cell carcinoma

Integrative analysis of deoxyribonuclease 1-like 3 as a potential biomarker in renal cell carcinoma

A Serum-Circulating Long Noncoding RNA Signature Can Discriminate Between Patients with Clear Cell Renal Cell Carcinoma and Healthy Controls.

Identification of a competing endogenous RNA network related to immune signature in clear cell renal cell carcinoma

Bioinformatic Analysis and Clinical Case Studies Identify CD276 as a Promising Diagnostic Biomarker for Clear Cell Renal Cell Carcinoma

Preoperative CT Radiomics Predicting the SSIGN Risk Groups in Patients with Clear Cell Renal Cell Carcinoma: Development and Multicenter Validation

Study of Clinical Predictive Value and Immune Characterization of SLFN11 in Clear Cell Renal Cell Carcinoma.

Overexpression of small nucleolar RNA SNORD1C is associated with unfavorable outcome in colorectal cancer

Identification of Snorna SNORA71A As a Novel Biomarker in Prognosis of Hepatocellular Carcinoma.